Tag Archives: biologics

Specialty Drugs: A Tempting Target, But What to Do?

A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, life-altering diseases.  The financial and reputational stakes for players in this hotly contested commercial space are high, compounded by a startling lack of awareness of the incentives that drive specific […]
Posted in Biotech, Market Access, Meetings, pricing, Strategy | Also tagged , , , , , , , | Leave a comment

Specialty Drugs and Reimbursement

To maximize return on investment, pharma must think strategically about reimbursement channels and how new specialty products will perform in one versus another. By 2018, the amount health insurers spend per person on specialty, or biologic drugs, will equal or surpass the amount spent on traditional products, according to a new report. With the emergence […]
Posted in Biotech, Strategy | Also tagged , , | Leave a comment

Can Sanofi's Expanding Predictive Modeling Technology Enhance the Productivity of R&D?

As the hurdles to successful commercialization of new medicines continue to mount, the ability to find and exploit cost efficiencies in the development process has become a critical source of competitive advantage.  This is true not only for biologic drugs but also increasingly for vaccines, now a high growth segment of the medicines business, with […]
Posted in Biotech | Also tagged , , | Leave a comment
  • Categories

  • Meta